Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
DNMT inhibitor
DRUG CLASS:
DNMT inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
decitabine (40)
decitabine/cedazuridine (10)
azacitidine oral (7)
NTX-301 (1)
OR-2100 (0)
ASTX030 (0)
RX-3117 (0)
SGI-110 (0)
decitabine (40)
decitabine/cedazuridine (10)
azacitidine oral (7)
NTX-301 (1)
OR-2100 (0)
ASTX030 (0)
RX-3117 (0)
SGI-110 (0)
›
Associations
(58)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
No biomarker
Myelodysplastic Syndrome
No biomarker
Myelodysplastic Syndrome
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
No biomarker
Chronic Myelomonocytic Leukemia
No biomarker
Chronic Myelomonocytic Leukemia
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
decitabine/cedazuridine
Sensitive: A1 - Approval
decitabine / cedazuridine
Sensitive
:
A1
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
decitabine/cedazuridine
Resistant: B - Late Trials
decitabine / cedazuridine
Resistant
:
B
decitabine/cedazuridine
Resistant: B - Late Trials
decitabine / cedazuridine
Resistant
:
B
TP53 mutation
Chronic Myelomonocytic Leukemia
TP53 mutation
Chronic Myelomonocytic Leukemia
decitabine/cedazuridine
Resistant: B - Late Trials
decitabine / cedazuridine
Resistant
:
B
decitabine/cedazuridine
Resistant: B - Late Trials
decitabine / cedazuridine
Resistant
:
B
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
decitabine
Sensitive: C2 – Inclusion Criteria
decitabine
Sensitive
:
C2
decitabine
Sensitive: C2 – Inclusion Criteria
decitabine
Sensitive
:
C2
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
decitabine
Sensitive: C2 – Inclusion Criteria
decitabine
Sensitive
:
C2
decitabine
Sensitive: C2 – Inclusion Criteria
decitabine
Sensitive
:
C2
DNMT3A mutation
Myelodysplastic Syndrome
DNMT3A mutation
Myelodysplastic Syndrome
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
U2AF1 mutation
Myelodysplastic Syndrome
U2AF1 mutation
Myelodysplastic Syndrome
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
NPM1 mutation
Myelodysplastic Syndrome
NPM1 mutation
Myelodysplastic Syndrome
decitabine
Sensitive: C3 – Early Trials
decitabine
Sensitive
:
C3
decitabine
Sensitive: C3 – Early Trials
decitabine
Sensitive
:
C3
DNMT3A mutation
Acute Myelogenous Leukemia
DNMT3A mutation
Acute Myelogenous Leukemia
decitabine/cedazuridine
Sensitive: C3 – Early Trials
decitabine / cedazuridine
Sensitive
:
C3
decitabine/cedazuridine
Sensitive: C3 – Early Trials
decitabine / cedazuridine
Sensitive
:
C3
KMT2A-PTD
Acute Myelogenous Leukemia
KMT2A-PTD
Acute Myelogenous Leukemia
cytarabine + decitabine + vorinostat
Sensitive: C3 – Early Trials
cytarabine + decitabine + vorinostat
Sensitive
:
C3
cytarabine + decitabine + vorinostat
Sensitive: C3 – Early Trials
cytarabine + decitabine + vorinostat
Sensitive
:
C3
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
decitabine + clofarabine
Sensitive: C3 – Early Trials
decitabine + clofarabine
Sensitive
:
C3
RUNX1 mutation
Acute Myelogenous Leukemia
RUNX1 mutation
Acute Myelogenous Leukemia
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
decitabine + cladribine
Sensitive: C3 – Early Trials
decitabine + cladribine
Sensitive
:
C3
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 inhibitor + venetoclax + decitabine
Sensitive: C3 – Early Trials
FLT3 inhibitor + venetoclax + decitabine
Sensitive
:
C3
FLT3 inhibitor + venetoclax + decitabine
Sensitive: C3 – Early Trials
FLT3 inhibitor + venetoclax + decitabine
Sensitive
:
C3
NRAS mutation
Acute Myelogenous Leukemia
NRAS mutation
Acute Myelogenous Leukemia
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
decitabine
Resistant: C3 – Early Trials
decitabine
Resistant
:
C3
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
decitabine + MBG453
Sensitive: C3 – Early Trials
decitabine + MBG453
Sensitive
:
C3
decitabine + MBG453
Sensitive: C3 – Early Trials
decitabine + MBG453
Sensitive
:
C3
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
MYC overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
WT1 overexpression
Myelodysplastic Syndrome
WT1 overexpression
Myelodysplastic Syndrome
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
cytarabine + decitabine + tretinoin
Sensitive
:
C3
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
cytarabine + decitabine + tretinoin
Sensitive
:
C3
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
cytarabine + decitabine + tretinoin
Sensitive
:
C3
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
cytarabine + decitabine + tretinoin
Sensitive
:
C3
ASXL1 mutation
Myelodysplastic Syndrome
ASXL1 mutation
Myelodysplastic Syndrome
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
cytarabine + decitabine + tretinoin
Sensitive
:
C3
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
cytarabine + decitabine + tretinoin
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login